

HENRY A. WAXMAN, CALIFORNIA
CHAIRMAN

JOHN D. DINGELL, MICHIGAN
CHAIRMAN EMERITUS
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
FRANK PALLONE, JR., NEW JERSEY
BART GORDON, TENNESSEE
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
GENE GREEN, TEXAS
DIANA DEGETTE, COLORADO
VICE CHAIRMAN
LOIS CAPPS, CALIFORNIA
MIKE DOYLE, PENNSYLVANIA
JANE HARMAN, CALIFORNIA
JAN SCHAKOWSKY, ILLINOIS
CHARLES A. GONZALEZ, TEXAS
JAY INSLEE, WASHINGTON
TAMMY BALDWIN, WISCONSIN
MIKE ROSS, ARKANSAS
ANTHONY D. WEINER, NEW YORK
JIM MATHESON, UTAH
G.K. BUTTERFIELD, NORTH CAROLINA
CHARLIE MELANCON, LOUISIANA
JOHN BARROW, GEORGIA
BARON P. HILL, INDIANA
DORIS O. MATSUI, CALIFORNIA
DONNA CHRISTENSEN, VIRGIN ISLANDS
KATHY CASTOR, FLORIDA
JOHN SARBANES, MARYLAND
CHRISTOPHER MURPHY, CONNECTICUT
ZACHARY T. SPACE, OHIO
JERRY MCNERNEY, CALIFORNIA
BETTY SUTTON, OHIO
BRUCE BRALEY, IOWA
PETER WELCH, VERMONT

JOE BARTON, TEXAS
RANKING MEMBER

RALPH M. HALL, TEXAS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITFIELD, KENTUCKY
JOHN SHIMKUS, ILLINOIS
JOHN B. SHADEGG, ARIZONA
ROY BLUNT, MISSOURI
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO MACK, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE ROGERS, MICHIGAN
SUE WILKINS MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE
PHIL GINGREY, GEORGIA
STEVE SCALISE, LOUISIANA

ONE HUNDRED ELEVENTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

MAJORITY (202) 225-2927
FACSIMILE (202) 225-2525
MINORITY (202) 225-3641

energycommerce.house.gov

February 19, 2009

Mr. Fred Hassan
Chairman of the Board, Chief Executive Officer
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033

Mr. Richard T. Clark
Chairman of the Board, President, Chief Executive Officer
Merck & Company, Inc.
One Merck Drive
P.O. Box 100
Whitehouse Station, NJ 08889

Dear Mr. Hassan and Mr. Clark:

The Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations are continuing an investigation into the safety and effectiveness of Vytorin, a prescription drug manufactured jointly by Schering-Plough and Merck.

On September 5, 2008, your counsel provided a briefing to Committee staff on a clinical trial called the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Your counsel stated that in January 2008, the Data Safety Monitoring Board for this trial, which is responsible for ensuring the safety of patients participating in the trial, requested that the Data Safety Monitoring Boards for two other large, ongoing Vytorin trials "unblind," or release, their study data prior to the conclusion of the studies. According to your counsel, the Data Safety Monitoring Boards for both of those trials — the Study of Heart and Renal Protection (SHARP) trial and the Examining Outcomes in Subjects with Acute Coronary Syndrome: Vytorin vs. Simvastatin (IMPROVE-IT) trial — agreed to do so.

We are writing to request information about the decisions by the Data Safety Monitoring Boards to unblind the interim data from the SHARP and IMPROVE-IT trials. Accordingly, we

Mr. Fred Hassan
Mr. Richard T. Clark
February 19, 2009
Page 2

request that Schering-Plough, Merck, and the joint venture of Schering-Plough and Merck produce the following documents and information by March 6, 2009:


1. The names, affiliations, and current contact information for all members of the Data Safety Monitoring Boards for the SEAS, SHARP, and IMPROVE-IT trials;
2. The names, affiliations, and current contact information for all members of the steering committees for the SEAS, SHARP, and IMPROVE-IT trials;
3. All documents relating to Institutional Review Board (IRB) approval and any subsequent IRB deliberations relating to the SEAS trial;
4. All minutes of Data Safety Monitoring Board meetings for the SEAS trial;
5. All communications relating to the SEAS trial between or among:
 - a. Any members of the SEAS trial's Data Safety Monitoring Board;
 - b. Any member of the SEAS trial's Data Safety Monitoring Board and any members of the SEAS, SHARP, or IMPROVE-IT steering committees;
 - c. Any member of the SEAS trial's Data Safety Monitoring Board and any investigators for the SEAS, SHARP, or IMPROVE-IT trials;
 - d. Any member of the SEAS trial's Data Safety Monitoring Board and any officers or employees of Merck, Schering-Plough, or the Merck/Schering-Plough joint venture;
6. All documents relating to the submission of the SEAS manuscript to the New England Journal of Medicine; and
7. All minutes of Data Safety Monitoring Board meetings for the SHARP and IMPROVE-IT trials no later than two weeks after the completion of those trials.

We request that Schering-Plough, Merck, and the joint venture of Schering-Plough and Merck retain without alteration, until further notice, all minutes, records, communications, and other documents relating to the Data Safety Monitoring Boards for the SEAS, SHARP, and IMPROVE-IT trials.

Mr. Fred Hassan
Mr. Richard T. Clark
February 19, 2009
Page 3

An attachment to this letter provides additional information on how to respond to the Committee's request. If you have any questions regarding this request, please contact Paul Jung of the Committee staff at (202) 226-2424.

Sincerely,


Henry A. Waxman
Chairman


Bart Stupak
Chairman
Subcommittee on Oversight and
Investigations

Enclosure

cc: Joe Barton
Ranking Minority Member
Committee on Energy and Commerce

cc: Greg Walden
Ranking Minority Member
Subcommittee on Oversight and Investigations